Atea Pharmaceuticals, Inc. reported financial results for the third quarter ended September 30, 2026, and provided an update on its clinical programs. The company announced that its Phase 3 C-BEYOND trial for hepatitis C virus (HCV) achieved its primary and secondary endpoints. The regimen of bemnifosbuvir/ruzasvir (BEM/RZR) demonstrated statistical non-inferiority to Epclusa (sofosbuvir/velpatasvir; SOF/VEL) in patients with HCV, meeting the trial's primary and secondary endpoints.
The topline results from C-BEYOND showed a 93.91% sustained virologic response (SVR) rate for BEM/RZR versus 94.75% for SOF/VEL in the modified intent-to-treat (mITT) population, which included 905 cirrhotic and non-cirrhotic patients. The regimen was generally safe and well tolerated, with a safety profile comparable to SOF/VEL. The company anticipates topline results from its Phase 3 C-FORWARD trial in early 2027, which is expected to support a New Drug Application (NDA) submission to the FDA targeted for mid-2027.
In addition to its HCV program, Atea is advancing its Hepatitis E (HEV) program. The company successfully completed the single ascending dose portion of its Phase 1 study for AT-587 and is currently conducting the multiple ascending dose portion. The company expects to initiate a proof-of-concept study in 2027.
On November 9, 2026, Atea announced a credit facility agreement with Hercules Capital, Inc. for up to $200 million. The facility strengthens the company's financial position and provides strategic and operational flexibility. Under the agreement, Atea drew down $65 million at closing on November 6, 2026. Based on its current operating plan and cash resources, the company anticipates these funds will support operations through mid-2028.
For the three months ended September 30, 2026, Atea reported cash and investments of $191.2 million. Research and development expenses decreased by $11.3 million to $27.1 million, while general and administrative expenses decreased by $0.3 million to $6.9 million. The company reported a net loss of $32.2 million for the quarter.
